seekingalpha.com
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth for 2025, indicating that it encounters problems in expanding its operations. The four relative valuations conducted in this article reported mixed results. These results suggest that the company trades at fair value.
